title: [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
abstract: OBJECTIVE
  To construct recombinant adenoviral vector expressing autocatalysis caspase-3 driven by human telomerase reverse transcriptase promoter amplified by two-step transcription amplification (hTERTp-TSTA), and investigate its antitumor effect in ovarian cancer in vitro and in vivo.
  
  
  METHODS
  Recombinant adenoviruses expressing autocatalytic caspase-3 (rev-caspase-3) driven by hTERTp-TSTA were prepared, which were named as AdHTVP2G5-rev-casp3. AdHT-rev-casp3, Ad-rev-casp3 and AdHTVP2G5-EGEP, which express rev-caspase-3 driven by hTERTp, cytomegalovirus promoter (CMVp) and enhanced green fluorescent protein (EGFP), respectively, were used as controls. Western blot, cell counting kit (CCK-8), flow cytometry (FCM) and TdT-mediated dUTP-biotin nick end labeling (TUNEL) were used to detect the expression of p17, active subunit of caspase-3, and p85, and to measure cell survival rates, apoptotic rates and cell cycle distribution in ovarian cell line AO and normal human umbilical vein endothelial cell line HUVEC, following treatments of AdHTVP2G5-rev-casp3. subcutaneous tumor models and abdominally spread tumor models of human ovarian carcinoma using AO cells in BALB/c nude mice were established. Following treatments of AdHTVP2G5-rev-casp3, western blot was used to detect the expression of active caspase-3 in abdominally spread tumors and liver tissues, respectively, and the mouse survival rates and the volume of tumor nodules were measured, and the serum level of alanine transaminase (ALT) and aspartate transaminase (AST) were analyzed to monitor liver damages and HE staining was used to detect the histopathological changes of various organs.
  
  
  RESULTS
  The levels of p17 expression in AdHTVP2G5-rev-casp3-treated AO cells were significantly higher than that in Ad-rev-casp3 or AdHT-rev-casp3 treated AO cells, while no expression was observed in AdHTVP2G5-rev-casp3-treated HUVEC. There was strong cell killing of AdHTVP2G5-rev-casp3 of hTERT positive AO cells, but not of the hTERT-negative HUVEC cells. Cell survival rate and apoptotic rate of AO cells treated with AdHTVP2G5-rev-casp3 were 17.8% and 40.2%, respectively, significantly different from that treated with AdHT-rev-casp3 (75.2% and 16.1%) at the multiplicity of infection (MOI) of 70 (P < 0.01). There was no significant difference in HUVEC cell survival rate and apoptotic rate between AdHTVP2G5-rev-casp3 treatment (97.7% and 2.1%, respectively) and AdHT-rev-casp3 treatment (98.5% and 1.7%, respectively) at the same MOI (P > 0.05). Significant expressions of active caspase-3 were shown in AdHTVP2G5-rev-casp3-treated tumors, whereas no expression was shown in liver. In contrast, both tumors and liver tissues showed active caspase-3 expression following treatments of Ad-rev-casp3. AdHTVP2G5-rev-casp3 and Ad-rev-casp3 prolonged mouse survival [mean survival time of (259 +/- 14) d and (213 +/- 16) d], when compared with treatment with AdHT-rev-casp3 [(177 +/- 12) d] and AdHTVP2G5-EGFP [(109 +/- 7) d; P < 0.01]. The mean volume of AdHTVP2G5-rev-casp3-treated tumor was 406 mm(3), significantly less than those of AdHT-rev-casp3 treatment (990 mm(3)), Ad-rev-casp3 treatment (645 mm(3)) and AdHTVP2G5-EGFP treatment (1728 mm(3); P < 0.01). The serum ALT and AST levels were not significantly elevated in AdHTVP2G5-rev-casp3-treated mice, whereas significantly elevated in Ad-rev-casp3-treated mice. No obvious lesions were found in any organ in AdHTVP2G5-rev-casp-treated group.
  
  
  CONCLUSIONS
  Recombinant adenovirus AdHTVP2G5-rev-casp3 expressing rev-caspase-3 driven by hTERTp-TSTA can result in marked cell apoptosis with significant tumor targeting, suppressing tumor growth and prolonging the mouse survival, meanwhile, it can prevent against the liver toxicity induced by rev-caspase-3.
authors.affiliation: Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Song
authors.forename: Keng
authors.initials: K
authors.lastname: Shen
authors.forename: Chun-Xia
authors.initials: CX
authors.lastname: He
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D017209:Apoptosis; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism*; D002384:Catalysis; D002460:Cell Line; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D053208:Kaplan-Meier Estimate; D008099:Liver / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010053:Ovary / Q000378:metabolism; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics*; D019098:Telomerase / Q000235:genetics*; D014162:Transfection; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D049452:Green Fluorescent Proteins; D019098:Telomerase; D053148:Caspase 3